Cell Suspension Cultures of Portulaca grandiflora as Potent Catalysts for Biotransformation of L-Tyrosine into L-DOPA, an Anti-Parkinson's Drug

By Rani Nisha   Joy Beena   Abraham T. Emilia  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 45, Iss. 1, 2007-01 ,pp. : 48-53

Informa Healthcare

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite

Novel L-Dopa and Dopamine Prodrugs Containing a 2-Phenyl-imidazopyridine Moiety

By Denora Nunzio   Laquintana Valentino   Lopedota Angela   Serra Mariangela   Dazzi Laura   Biggio Giovanni   Pal Dhananjay   Mitra Ashim   Latrofa Andrea   Trapani Giuseppe   Liso Gaetano  

Pharmaceutical Research, Vol. 24, Iss. 7, 2007-07 ,pp. : 1309-1324

Springer Publishing Company

Access to resources Recommend Favorite

L-Dopa Prodrugs: An Overview of Trends for Improving Parkinson's Disease Treatment

By  

Current Pharmaceutical Design, Vol. 17, Iss. 32, 2011-11 ,pp. : 3482-3493

Bentham Science Publishers

Access to resources Recommend Favorite

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation

By Parada A.   Loureiro A.I.   Vieira-Coelho M.A.   Hainzl D.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 27-32

Elsevier

Access to resources Recommend Favorite